AstraZeneca Korea acquired an approval for the asthma and COPD inhaler ‘Symbicort Rapihaler’

Published: 2015-06-17 13:34:52

Updated: 2015-06-17 13:34:52

The AstraZeneca Korea’s(President Liz Chatwin) asthma and chronic obstructive pulmonary disease(COPD) treatment ‘Symbicort Rapihaler(budesonide + formoterol)’ has recently been approved from the Ministry of Food and Drug Safety.

The recently-approved ‘Symbicort Rapihaler,’ a ICS/LABA(inhaled corticosteroid and long acting β2-agonist) complex inhaler for the asthma and COPD treatment, will be l...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.